Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAGBiotechnology
+$2.32 today
- Market cap
- $1.83B
- Beta
- 0.00
Volume 0.30M
Average 0.34M
COAG Other Non-current Assets
Long-term assets not reported separately.
Hemab Therapeutics Holdings, Inc. Common StockNASDAQ: COAG
Other Non-current Assets · Q2 FY2026 · quarter ended Jun 2026
Other non-current assets of $2.29M in Q2 FY2026
Q2 FY2026 other non-current assets was $2.29M.
Context
- Other non-current assets amounted to 0.5% of total assets at the end of Q2 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 531K USD
- Year-over-year change
- —
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 531K | — |
Other Non-current Assets vs competitors
How COAG compares with its peers on the latest reported figures
- COAG's Jun 2026 other non-current assets of $2.29M is the 2nd highest of the 5 companies compared; the peer median is $653K.
- Other non-current assets amounts to 0.5% of total assets for COAG, versus a peer median of 0.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $5.54M | +2.1% | -2.8% | 0.7% | |
COAGHemab Therapeutics Holdings, Inc. Common Stock | Jun 2026 | $2.29M | — | — | 0.5% |
| Mar 2026 | $810K | — | — | 1.5% | |
IRONDisc Medicine, Inc. | Sep 2026 | $496K | -34.2% | +84.3% | 0.1% |
DMRADamora Therapeutics, Inc. | Mar 2026 | $34K | -98.2% | — | 0.0% |
| Peer median (excluding COAG) | $653K | -34.2% | +40.7% | 0.4% | |
Competitors are the stored peer set for COAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAG
Intrinsic Alpha fair value
Locked
Current Price
$39.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.